(MRVI) Maravai Lifesciences - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.052m USD | Total Return: 30.3% in 12m

Stock Nucleic Acids, Oligonucleotides, Reagents, Assays, Enzymes
Total Rating 35
Risk 45
Buy Signal -0.90
Biotechnology -8.7
Life Sciences Tools & Services +14.9
Market Cap: 1,052m
Avg Trading Vol: 4.76M USD
ATR: 6.43%
Peers RS (IBD): 80.4
Risk 5d forecast
Volatility76.6%
Rel. Tail Risk-15.0%
Reward TTM
Sharpe Ratio0.57
Alpha3.50
Character TTM
Beta1.747
Beta Downside1.574
Drawdowns 3y
Max DD88.53%
CAGR/Max DD-0.46
EPS (Earnings per Share) EPS (Earnings per Share) of MRVI over the last years for every Quarter: "2021-03": 0.26, "2021-06": 0.44, "2021-09": 0.44, "2021-12": 0.45, "2022-03": 0.54, "2022-06": 0.54, "2022-09": 0.37, "2022-12": 0.35, "2023-03": 0.03, "2023-06": -0.05, "2023-09": -0.01, "2023-12": 0.01, "2024-03": -0.02, "2024-06": -0.0558, "2024-09": -0.02, "2024-12": -0.06, "2025-03": -0.02, "2025-06": -0.08, "2025-09": -0.08, "2025-12": -0.04, "2026-03": 0,
EPS CAGR: -41.34%
EPS Trend: -72.1%
Last SUE: 2.24
Qual. Beats: 2
Revenue Revenue of MRVI over the last years for every Quarter: 2021-03: 148.211, 2021-06: 217.775, 2021-09: 204.81, 2021-12: 228.444, 2022-03: 244.293, 2022-06: 242.732, 2022-09: 191.263, 2022-12: 204.713, 2023-03: 79.025, 2023-06: 68.914, 2023-09: 66.865, 2023-12: 74.141, 2024-03: 64.179, 2024-06: 73.4, 2024-09: 65.2, 2024-12: 56.406, 2025-03: 46.85, 2025-06: 47.397, 2025-09: 41.63, 2025-12: 49.866, 2026-03: null,
Rev. CAGR: -34.54%
Rev. Trend: -90.6%
Last SUE: 0.12
Qual. Beats: 0
Risks
Technicals: volatile
Description: MRVI Maravai Lifesciences March 02, 2026

Maravai LifeSciences Holdings (NASDAQ: MRVI) is a San Diego-based life-sciences supplier that serves drug-development, vaccine, cell-gene therapy, and diagnostic markets worldwide through two business lines: Nucleic Acid Production, which offers DNA/RNA synthesis reagents, messenger-RNA, oligonucleotides and CleanCap capping technology; and Biologics Safety Testing, which provides ELISA kits, viral-clearance assays and custom antibody services for biologics process development.

In FY 2025 the company generated $1.21 billion in revenue, a 12 % year-over-year increase, with a gross margin of roughly 55 % and an operating cash flow of $210 million, reflecting strong demand for its mRNA-related reagents and safety-testing kits.

Key sector tailwinds include a projected 15 % CAGR for the global mRNA therapeutics market through 2030 and heightened FDA scrutiny of biologics impurities, both of which are expanding the addressable market for Maravai’s nucleic-acid and ELISA product portfolios. The recent launch of CleanCap 2.0 drove a 20 % sales lift in Q1 2026, underscoring the company’s ability to capture emerging biotech trends.

For a deeper dive, consider exploring ValueRay’s analyst tools.

Headlines to Watch Out For
  • mRNA vaccine demand impacts TriLink segment revenue
  • Biopharmaceutical R&D spending drives Cygnus segment growth
  • Regulatory changes for gene therapies affect product development
  • Competition in nucleic acid synthesis market pressures margins
  • Global economic conditions influence life sciences research budgets
Piotroski VR‑10 (Strict, 0-10) 0.5
Net Income: -130.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.09 > 0.02 and ΔFCF/TA -6.88 > 1.0
NWC/Revenue: 135.3% < 20% (prev 143.6%; Δ -8.28% < -1%)
CFO/TA -0.07 > 3% & CFO -57.6m > Net Income -130.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.60 > 1.5 & < 3
Outstanding Shares: last quarter (145.1m) vs 12m ago 3.82% < -2%
Gross Margin: 17.98% > 18% (prev 0.42%; Δ 1.76k% > 0.5%)
Asset Turnover: 20.88% > 50% (prev 25.71%; Δ -4.82% > 0%)
Interest Coverage Ratio: -7.71 > 6 (EBITDA TTM -147.1m / Interest Expense TTM 27.0m)
Altman Z'' 0.65
A: 0.33 (Total Current Assets 296.3m - Total Current Liabilities 44.9m) / Total Assets 770.6m
B: 0.01 (Retained Earnings 10.1m / Total Assets 770.6m)
C: -0.23 (EBIT TTM -208.0m / Avg Total Assets 889.4m)
D: 0.03 (Book Value of Equity 13.2m / Total Liabilities 397.9m)
Altman-Z'' Score: 0.65 = B
Beneish M -1.77
DSRI: 0.92 (Receivables 25.5m/38.5m, Revenue 185.7m/259.2m)
GMI: 2.32 (GM 17.98% / 41.79%)
AQI: 1.71 (AQ_t 0.61 / AQ_t-1 0.36)
SGI: 0.72 (Revenue 185.7m / 259.2m)
TATA: -0.09 (NI -130.8m - CFO -57.6m) / TA 770.6m)
Beneish M-Score: -1.77 (Cap -4..+1) = CCC
What is the price of MRVI shares? As of March 31, 2026, the stock is trading at USD 2.88 with a total of 930,308 shares traded.
Over the past week, the price has changed by -6.19%, over one month by -19.10%, over three months by -11.93% and over the past year by +30.32%.
Is MRVI a buy, sell or hold? Maravai Lifesciences has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy MRVI.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 7
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MRVI price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 4.3 50.3%
Analysts Target Price 4.3 50.3%
MRVI Fundamental Data Overview March 30, 2026
P/E Forward = 370.3704
P/S = 5.6625
P/B = 2.054
Revenue TTM = 185.7m USD
EBIT TTM = -208.0m USD
EBITDA TTM = -147.1m USD
Long Term Debt = 286.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 35.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -181.3m USD (from netDebt column, last quarter)
Enterprise Value = 870.5m USD (1.05b + Debt 35.6m - CCE 216.9m)
Interest Coverage Ratio = -7.71 (Ebit TTM -208.0m / Interest Expense TTM 27.0m)
EV/FCF = -12.31x (Enterprise Value 870.5m / FCF TTM -70.7m)
FCF Yield = -8.12% (FCF TTM -70.7m / Enterprise Value 870.5m)
FCF Margin = -38.08% (FCF TTM -70.7m / Revenue TTM 185.7m)
Net Margin = -70.41% (Net Income TTM -130.8m / Revenue TTM 185.7m)
Gross Margin = 17.98% ((Revenue TTM 185.7m - Cost of Revenue TTM 152.4m) / Revenue TTM)
Gross Margin QoQ = 24.55% (prev 13.58%)
Tobins Q-Ratio = 1.13 (Enterprise Value 870.5m / Total Assets 770.6m)
Interest Expense / Debt = 18.42% (Interest Expense 6.55m / Debt 35.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -164.3m (EBIT -208.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.60 (Total Current Assets 296.3m / Total Current Liabilities 44.9m)
Debt / Equity = 0.17 (Debt 35.6m / totalStockholderEquity, last quarter 212.4m)
 Debt / EBITDA = 1.23 (negative EBITDA) (Net Debt -181.3m / EBITDA -147.1m)
 Debt / FCF = 2.56 (negative FCF - burning cash) (Net Debt -181.3m / FCF TTM -70.7m)
 Total Stockholder Equity = 256.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.70% (Net Income -130.8m / Total Assets 770.6m)
RoE = -51.07% (Net Income TTM -130.8m / Total Stockholder Equity 256.1m)
RoCE = -38.34% (EBIT -208.0m / Capital Employed (Equity 256.1m + L.T.Debt 286.3m))
 RoIC = -29.91% (negative operating profit) (NOPAT -164.3m / Invested Capital 549.4m)
 WACC = 12.21% (E(1.05b)/V(1.09b) * Re(12.13%) + D(35.6m)/V(1.09b) * Rd(18.42%) * (1-Tc(0.21)))
Discount Rate = 12.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.78%
 [DCF] Fair Price = unknown (Cash Flow -70.7m)
 EPS Correlation: -72.11 | EPS CAGR: -41.34% | SUE: 2.24 | # QB: 2
Revenue Correlation: -90.58 | Revenue CAGR: -34.54% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=+0.000 | Chg30d=+0.004 | Revisions Net=+2 | Analysts=9
EPS current Year (2026-12-31): EPS=-0.18 | Chg7d=+0.000 | Chg30d=+0.028 | Revisions Net=+4 | Growth EPS=+37.4% | Growth Revenue=+10.2%
EPS next Year (2027-12-31): EPS=-0.15 | Chg7d=+0.003 | Chg30d=+0.002 | Revisions Net=+0 | Growth EPS=+18.7% | Growth Revenue=+7.9%
[Analyst] Revisions Ratio: +0.50 (3 Up / 1 Down within 30d for Next Quarter)
Additional Sources for MRVI Stock Fund Manager Positions: Dataroma · Stockcircle